AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT06659549
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient will apply daily 2 eye drops of Placebo at 5 minutes interval
Trial: NCT05972564
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo consists of gelatin capsules.
Trial: NCT00484991
Drug: Sapropterin dihydrochloride
RxNorm normalized name: Sapropterin Dihydrochloride
DrugBank: Sapropterin (DB00360)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 20mg/kg/day orally, physicians may adjust the dose within a range of 5-20mg/kg/day as warranted by their clinical judgment.
Trial: NCT05148533
Drug: TJ1133 Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TJ011133 (30 mg/kg, 45 mg/kg,QW) in combination with toripalimab injection (240 mg, Q3W)
Trial: NCT06253117
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT06148662
Drug: Dental foam Biorepair PERIBIOMA
RxNorm normalized name: DIBASIC CALCIUM PHOSPHATE DIHYDRATE 15.11 g in 100 g ORAL PASTE [Biorepair Total Protection]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The participants will be asked to hold 20 ml of coca-cola in their mouth for 30 seconds.~Then, participants will use a dental foam Biorepair PERIBIOMA to rinse their mouth. They should rinse their mouth for 60 seconds and then spit out the foam.
Trial: NCT06148662
Drug: Dental spray BUCCOTHERM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The participants will be asked to hold 20 ml of coca-cola in their mouth for 30 seconds.~Then, participants will use a dental spray BUCCOTHERM to rinse their mouth. They should rinse their mouth for 60 seconds and then spit out the foam.
Trial: NCT05321732
Drug: DWP16001
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DWP16001 A mg
Trial: NCT05321732
Drug: DWP202010
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DWP202010 B mg
Trial: NCT04916613
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: po, b.i.d.
Trial: NCT04916613
Drug: Androgen deprivation therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Use according to local standard of care
Trial: NCT06347068
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: cyclophosphamide 300 mg/m2 IV will be given.
Trial: NCT00160745
Drug: Rosuvastatin
RxNorm normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT04933240
Drug: Estradiol
RxNorm normalized name: Estradiol
DrugBank: Estradiol acetate (DB13952)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: estradiol tablets for oral administration contains 1 mg of micronized estradiol per tablet.
Trial: NCT04933240
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A sugar tablet that does not contain any active medicine
Trial: NCT06218056
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The placebo softgel capsule formulation will have a composition with the same relative proportions as the CBD ATL5 Softgel Capsules. This formulation will be manufactured by Baxco Pharmaceutical Inc under cGMP conditions. 4 softgel capsules of placebo will be administered to match the capsule number of the active compound, daily in the morning and evening for each of 56 days.
Trial: NCT05155293
Drug: Eylea® (Aflibercept)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive IVT injections of Eylea®
Trial: NCT06679322
Drug: Androtriol Injection (High-dose group)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive 30 mL of Androtriol Injection per dose, administered every 12 hours for 7 consecutive days. Each infusion will be administered over a period of 30±5 minutes.
Trial: NCT05489796
Drug: Fentanyl selector
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Selector (1 ml; Lock out 10 min): Fentanyl 200 mcg + N/S 16 ml = total 20 ml
Trial: NCT05489796
Drug: Fentanyl continuous
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Continuous (2 ml/hr): fentanyl 700 mcg + N/S 86 ml = total 100 ml
Trial: NCT05489796
Drug: Ketorolac continuous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous (2 ml/hr): Ketorolac 180 mg + N/S 94 ml = total 100 ml
Trial: NCT04973800
Drug: Simvastatin 20mg
RxNorm normalized name: SIMVASTATIN 20MG TAB
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Simvastatin 20mg ON PO for 28-30 days
Trial: NCT05556226
Drug: ABBV-154 Dose Formulation B
RxNorm normalized name: Hep B, unspecified formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous Injection
Trial: NCT05347394
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo matched to VX-708 for oral administration.
Trial: NCT02371096
Drug: RGB-03
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT05108259
Drug: PBP1502
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg/0.4 mL single SC injection via PFS
Trial: NCT05108259
Drug: EU-licensed Humira
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg/0.4 mL single SC injection via PFS
Trial: NCT05108259
Drug: US-licensed Humira
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg/0.4 mL single SC injection via PFS
Trial: NCT05615272
Drug: Alveogyl
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group
Trial: NCT04676646
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo comparator
Trial: NCT06214637
Drug: Melissa
RxNorm normalized name: Indian melissa oil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The test solutions will be administered once a day through administration in drops for children between 5 and 10 years old and for adolescents between 11 and 16 years old. As participants will be between 5 and 16 years old, children will be given a minimum of 5 and a maximum of 10 drops of the solutions per individual (Tavares-Silva, Holandino et al. 2019) as well as a maximum of 10 drops for adolescents of solutions per individual (Taylor, Lancaster et al. 2000). Highlighting that the prescription of Melissa officinalis will be at night, around 20/30 minutes before bedtime, respecting the indications for the medications described in the Hahnemannian Materia Medica (Vijnovsky, 2003). All medications must be taken away from meals and they will be instructed not to use mentholated substances, respecting a minimum time of 30 minutes.
Trial: NCT06214637
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: It will be administered for a period of 30 days, once a day before bed, with a 15-day wash-out interval. The placebo, a drug without active substance, that will be administered to research participants will be the biotherapeutic vehicle, that is, 30% alcohol (v/v), which is commonly used as a vehicle for homeopathic medicines.
Trial: NCT02978651
Drug: Placebo Oral Tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04832776
Drug: FOLFOXIRI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FOLFOXIRI
Trial: NCT05856058
Drug: SHR0302
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SHR0302 oral solution 1 time, SHR0302 tablets 1 time
Trial: NCT05522634
Drug: TJAOA101
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once enrolled, participants will be administrated TJAOA101
Trial: NCT04694703
Drug: Covid-19 group
RxNorm normalized name: covid-19, protein subunit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine COVID-19 treatment
Trial: NCT05922709
Drug: CS12192 capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants receive CS12192 orally single or multiple doses
Trial: NCT05922709
Drug: Placebo capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants receive placebo matching CS12192 orally single or multiple doses
Trial: NCT05974033
Drug: Medical therapy alone
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medical therapy alone: received aspirin, 100mg, plus clopidogrel, 75 mg, daily for 90 days after randomisation.
Trial: NCT04334408
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo injections during the run in and washout serves as the control condition. Both the subject and the investigator will be blinded to the timing of transition to and from placebo and the transition to and from fremanezumab.
Trial: NCT03649464
Drug: OKN-007
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose escalation/PK cohort (Phase Ib): 1000mg twice daily (BID), 1000mg thrice daily (TID), 1500mg thrice daily (TID).~Expansion cohort (Phase 2): MTD defined in the dose escalation (Phase Ib) study.
Trial: NCT06526793
Drug: AZD0486
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Investigational Product administered via intravenous infusion.
Trial: NCT05289557
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sugar pills with no active ingredients. Minimum 1 tablet at bedtime. Up to two pills daily (one tablet in the morning and one tablet at bedtime). The treatment duration is 15 days.
Trial: NCT05425745
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo tablet made to resemble active
Trial: NCT06678113
Drug: BSG005
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single arm dose escalation in patients with invasive fungal infection
Trial: NCT06678685
Drug: .spironolactone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In the first week, the starting dose is 2mg/Kg per body weight once a day, taken with food at lunch every day, and subsequently adjusted according to the situation. If the patient's serum potassium is ≤5.0 mEq/L and the patient's serum creatinine is ≤2.5 mg/dL, treatment should be initiated with 25 mg spironolactone once daily. Increased to 100mg after remission. If the results are not obvious in the first month, increase the drug dose to 3mg/Kg.
Trial: NCT05848440
Drug: AZD9550
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will be administered AZD9550 subcutaneously.
Trial: NCT05848440
Drug: AZD9550
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will be administered AZD9550 intravenously.
Trial: NCT05848440
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will be administered matching volumes of placebo subcutaneously or intravenously.
Trial: NCT04899921
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Taken orally
Trial: NCT04856774
Drug: SHR-1701；BP102
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug: SHR-1701 IV infusion~Drug: BP102 IV infusion~Phase Ib: SHR-1701 30mg/kg + BP102 15mg/kg Q3w as starting dose, until recommended phase 2 dose is determined.
Trial: NCT06277050
Drug: Maintenance Therapy with Toripalimab and Capecitabine
RxNorm normalized name: Toripalimab
DrugBank: Toripalimab (DB15043)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capecitabine maintenance therapy (1000 mg/m2 orally twice daily on days 1-14) every 3 weeks. Maintenance therapy of Toripalimab (240 mg, every 3 weeks). The total treatment time of oral chemotherapy is 12 months.
Trial: NCT06277050
Drug: Maintenance Therapy with Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Capecitabine maintenance therapy (1000 mg/m2 orally twice daily on days 1-14) every 3 weeks. The total treatment time of oral chemotherapy is 12 months.
Trial: NCT05719831
Drug: vonoprazan fumarate + low dose amoxicillin（L-10d)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: vonoprazan fumarate 20 mg/time, 2 times/day, oral Amoxicillin1000mg/ time, 2 times/day, oral, for 10d
Trial: NCT05719831
Drug: vonoprazan fumarate + amoxicillin（H-14d)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: vonoprazan fumarate 20 mg/time, 2 times/day, oral Amoxicillin 750mg/ time, 4 times/day, oral, for 14d
Trial: NCT06616389
Drug: ODX (Osteodex)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multi-center, prospective, open-label, ascending dose study to evaluate safety and biological efficacy of up to 3 dose levels of ODX.
Trial: NCT06663631
Drug: Placebo group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 ml saline solution was set as placebo and delivered intravenously at the beginning of endovascular thrombectomyat a velocity of 4ml/h. The whole period of drug delivery lasts for approximately 12h.
Trial: NCT04770012
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: patients randomized to placebo study group will be dispensed placebo capsules to be taken daily for the duration of the treatment
Trial: NCT06012578
Drug: ISM5411
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Investigational Drug
Trial: NCT06012578
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ISM5411 Matching Placebo
Trial: NCT06019117
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: clinical trial using 90 days of placebo controlled
Trial: NCT06744751
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Manufactured by the same company, the placebo capsules contain starch as the main ingredient and are identical in appearance, size, color, dosage form, weight, and taste to the FMT capsules. They are administered once daily, 4 capsules per dose, for 12 days.
Trial: NCT06001762
Drug: LHRH Agonist
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Luteinizing hormone-releasing hormone agonist), taken orally per institutional standard of care
Trial: NCT06678282
Drug: JY231 Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The starting dose of this study was set at 1\~10×10\^6 transduction units (TU) / kg and escalated at 2\~5×107\^TU/kg and 6\~10×10\^7 TU/kg.
Trial: NCT06650124
Drug: Mycophenolate Mofetil + Prednisolone Participants will receive mycophenolate mofetil in combination.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants in this arm will receive mycophenolate mofetil (MMF) starting at 1,000 mg/day for the first two weeks, increasing to 2,000 mg/day thereafter. This will be combined with prednisolone, beginning at 40-60 mg/day, with a tapering dose to 5-10 mg/day after 4-8 weeks, depending on the patient's response. MMF works by inhibiting inosine monophosphate dehydrogenase, which decreases lymphocyte proliferation, thereby reducing immune-mediated liver damage in autoimmune hepatitis. Prednisolone, a corticosteroid, is included to control inflammation during the induction phase of treatment. This intervention lasts for 24 weeks, with monitoring for biochemical remission (normalization of liver enzymes and IgG levels) and adverse events to assess the treatment's safety and efficacy.
Trial: NCT06650124
Drug: Azathioprine + Prednisolone
RxNorm normalized name: Azathioprine
DrugBank: Azathioprine (DB00993)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: In this arm, participants will receive azathioprine (AZA) starting at 50 mg/day for the first two weeks, followed by an increase to 100 mg/day. This dose will be combined with prednisolone, starting at 40-60 mg/day, with the dosage tapering to 5-10 mg/day after 4-8 weeks, depending on patient response. Azathioprine works as an immunosuppressive agent by inhibiting DNA synthesis in rapidly dividing immune cells, thereby reducing liver inflammation in autoimmune hepatitis. Prednisolone, a corticosteroid, is included to control inflammation during the initial treatment phase. The intervention lasts for 24 weeks with regular monitoring for biochemical remission, defined as normalization of liver enzymes (AST, ALT) and IgG levels, as well as the occurrence of adverse events to assess safety and tolerability.
Trial: NCT03417206
Drug: Remifentanil
RxNorm normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: a rate of infusion will be increased by 50% every 5 minutes until PRD decreases below 5%
Trial: NCT04608630
Drug: Zoledronic Acid 5Mg/Bag 100Ml Inj
RxNorm normalized name: ZOLEDRONIC ACID 5MG/BAG 100ML INJ
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients allocated to the Zoledronic acid arm will receive Zoledronic acid 5mg in 100ml 0.9% Sodium Chloride or 5% Dextrose, administered via intravenous infusion over at least 15 minutes on Study Day 1.
Trial: NCT06427044
Drug: Anterior serratus block group
RxNorm normalized name: Fucus serratus extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bupivacaine lipid 20mL (20mL 266mg bupivacaine liposomes) was ultrasound-guided for a single anterior serranus plane block
Trial: NCT04954859
Drug: Bepirovirsen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No study drug will be administered in this study. Eligible participants who received prior treatment with bepirovirsen in the parent studies will be included.
Trial: NCT04954859
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No study drug will be administered in this study. Eligible participants who received prior treatment with placebo in the parent studies (209668, 202009, and 219288) will be included to maintain the blind in the still ongoing parent studies.
Trial: NCT04913519
Drug: TDM-105795
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TDM-105795 topical solution
Trial: NCT04913519
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo for TDM-105795 topical solution
Trial: NCT05782608
Drug: IV ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Group 1 will receive IV ibuprofen 400mg \\ 6 hours the first dose will be administrated immediately post operative.
Trial: NCT05782608
Drug: IV ketorolac
DrugBank: Ketorolac (DB00465)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Group 2 will receive 20 mg IV ketorolac\\ 6 hours the first dose will be administrated immediately post operative
Trial: NCT04684511
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching Placebo
Trial: NCT05903339
Drug: V3G CH848 Pr-NP1 60mcg
RxNorm normalized name: Bacillus anthracis strain V770-NP1-R antigens Injectable Suspension [Biothrax]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: (60 mcg)
Trial: NCT05903339
Drug: 3M-052-AF 5mcg
RxNorm normalized name: Canesten AF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: (5 mcg)
Trial: NCT05903339
Drug: ACU-026-001-1 2.0mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: (2.0 mg)
Trial: NCT05903339
Drug: V3G CH848 Pr-NP1 100mcg
RxNorm normalized name: Bacillus anthracis strain V770-NP1-R antigens Injectable Suspension [Biothrax]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: (100 mcg)
Trial: NCT04410224
Drug: ASN004
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ASN004 is an antibody-drug conjugate for the treatment of advanced or metastatic solid tumors.
Trial: NCT05945810
Drug: TLL-018 extended-release tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50mg TLL-018 extended-release tablet QD
Trial: NCT04282239
Drug: Lidocaine Epinephrine
RxNorm normalized name: epinephrine / lidocaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mL on each side of anterior chest for a total of 20mL
Trial: NCT05367635
Drug: SKB315 for injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SKB315 for injection is an Antibody Drug Conjugates (ADC) drug targeting Claudin18.2. The strength of SKB315 is 200 mg/vial.
Trial: NCT04832971
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sterile Normal Saline (0.9% NaCl)
Trial: NCT05152901
Drug: EpiPen ®.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A single dose of 0.3 mg epinephrine via intramuscular injection into the anterolateral aspect of the thigh on Day 1 Visit 2.
Trial: NCT05152901
Drug: Epinephrine (0.3mg) inhaled
RxNorm normalized name: epinephrine Inhalation Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will be administered 0.3mg of first inhaled dose of epinephrine once daily on day 2 of Visit 2
Trial: NCT05152901
Drug: Epinephrine (1.3mg)
RxNorm normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: A single inhaled dose or split into 2 administrations (administered less than 1 minute apart) of a planned dose of 1.3 mg epinephrine.
Trial: NCT05152901
Drug: Epinephrine (4mg)
RxNorm normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: A single inhaled dose or split into 2 administrations (administered less than 1 minute apart) of a planned dose of 4 mg epinephrine
Trial: NCT04747795
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV
Trial: NCT05385575
Drug: KN056 (0.1mg)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The participants will receive assigned single dose of KN056 on Day 1
Trial: NCT05546242
Drug: Antiretroviral
RxNorm normalized name: Antiretroviral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral antiretroviral therapy in the form of 2NRTIs + dolutegravir 50mg administered daily
Trial: NCT05385575
Drug: KN056 (0.3mg)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The participants will receive assigned single dose of KN056 on Day 1
Trial: NCT05385575
Drug: KN056 (1.0mg)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The participants will receive assigned single dose of KN056 or placebo on Day 1
Trial: NCT05385575
Drug: KN056 (3.0mg)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The participants will receive assigned single dose of KN056 or placebo on Day 1
Trial: NCT06679673
Drug: SHR2554
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SHR2554
Trial: NCT05385575
Drug: KN056 (6.0mg)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The participants will receive assigned single dose of KN056 or placebo on Day 1
Trial: NCT05385575
Drug: KN056 (12.0mg)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The participants will receive assigned single dose of KN056 or placebo on Day 1